JPRN-jRCT2080220889未知3 期
A Randomized, Double-Blind Placebo-Controlled, Comparative Study of S-1 in Patients with Advanced Hepatocellular Carcinoma Failure to Sorafenib monotherapy
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients who are able to do oral administration
- •2)Patients who have the history of histologically and cytologically confirmed primary hepatocellular carcinoma.
- •3)Hepatocellular carcinoma patients who are failure to sorafenib monotherapy.
- •4)Life expectancy of 60 days or more following the start of treatment
- •5)Patients with written informed consent.
排除标准
- 未提供
研究者
相似试验
招募中
2 期
The Effect of Ocitum™ (Tulsi Leaf Extract) on Depression, Anxiety, Stress, and Sleep Quality.CTRI/2024/03/063413K Patel Phytoextractions Pvt Ltd.
已完成
不适用
efficacy and safety of probiotic butter spread (probiotic food)CTRI/2021/02/031551Zydus Wellness Limited101
已完成
不适用
Effect of Test Products on Immune Markers and Gut Health In Elderly PopulatioCTRI/2020/03/023865Tata Chemicals Ltd199
已完成
3 期
A clinical trial to study the effect of Apremilast Tablets in the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.CTRI/2016/10/007345Glenmark Pharmaceuticals Ltd
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 16.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-CZRadius Health, Inc.2,400